Chemical Industry Weekly News Round-Up, Oct. 28

This Week on CW:

In Europe, third-quarter sales rose, but higher revenues squeezed margins. Most companies acknowledged that they were experiencing some slowdown due to the soft economy.

Outside earnings, CPhI 2011 was held this week in Frankfurt. Pharma ingredient makers were generally optimistic, but a bit apprehensive about coming changes in the industry as a number of products come off-patent.

Meanwhile, China is imposing antidumping duties on caprolactam from the U.S. and E.U. for five years.

Around the Web:

Recalibration means that already-flimsy economic models, widely used by Wall Street banks and big companies, are frequently wrong, in Scientific American.

A blogger says that “the IPO window has closed” for biotech, in BiotechNow.

An article in Physics Today uses climate change as an example of the difficulty in explaining scientific concepts clearly and concisely.